Cagrilintide vs AM833 — Key Differences Explained

Cagrilintide and AM833 represent two distinct approaches to metabolic regulation. One through amylin receptor agonism, the other through dual incretin pathway activation. Cagrilintide, a long-acting amylin analog, extends gastric emptying time and suppresses glucagon secretion primarily through the amylin receptor (AMY receptor), while AM833 functions as a dual GLP-1 and GIP receptor agonist, modulating both insulin secretion and appetite signaling centrally. A 2024 Phase 2 trial published in The Lancet Diabetes & Endocrinology demonstrated that cagrilintide monotherapy produced mean weight reduction of 10.8% at 32 weeks, while AM833's Phase 1 data showed rapid glucose-dependent insulin secretion within 30 minutes of administration. Fundamentally different timelines and mechanisms.

Our team has worked with researchers evaluating both peptides for metabolic studies. The most common confusion we encounter is assuming they're simply 'next-generation GLP-1s'. They're not. One slows the gut; the other activates hormonal pathways that GLP-1 alone doesn't reach.

What's the difference between cagrilintide and AM833?

Cagrilintide is a long-acting amylin receptor agonist that reduces food intake by slowing gastric emptying and suppressing glucagon, with a half-life of approximately 7 days allowing weekly dosing. AM833 is a dual GLP-1 and GIP receptor agonist that enhances glucose-dependent insulin secretion and reduces appetite through central hypothalamic signaling, currently in early-phase clinical development. Cagrilintide has advanced to Phase 3 trials in combination with semaglutide, while AM833 remains in Phase 1/2 studies evaluating safety and pharmacokinetics.

Both peptides emerged from efforts to address the metabolic limitations of single-pathway interventions. But the pathways they target, the timelines they operate on, and the clinical endpoints they've demonstrated differ substantially. Cagrilintide's amylin mechanism creates gastric delay that compounds GLP-1's satiety effects when co-administered, which is why Novo Nordisk's CagriSema (cagrilintide + semaglutide) combination produced 15.6% mean weight reduction in the STEP trials. Meaningfully above semaglutide monotherapy. AM833's dual GIP/GLP-1 action resembles tirzepatide's mechanism but with structural modifications intended to optimize receptor binding affinity and reduce GI side effects. This article covers the receptor pathways each peptide activates, how their pharmacokinetics dictate dosing schedules, which clinical trial phases they've completed, and what those results mean for researchers selecting between amylin-based and incretin-based compounds.

Mechanism of Action: Amylin vs Dual Incretin Pathways

Cagrilintide works by binding to the amylin receptor. A G-protein-coupled receptor complex formed by the calcitonin receptor (CTR) and receptor activity-modifying proteins (RAMPs). This binding mimics endogenous amylin, a hormone co-secreted with insulin from pancreatic beta cells that regulates postprandial glucose by three mechanisms: slowing gastric emptying (extending the time nutrients enter the small intestine), suppressing postprandial glucagon secretion (reducing hepatic glucose output), and reducing food intake through central appetite signaling in the area postrema. The extended half-life. Approximately 165 hours. Is achieved through albumin binding via a fatty acid side chain, allowing once-weekly subcutaneous administration. Clinical data from the Phase 2 REWIND-1 trial showed cagrilintide 2.4mg weekly reduced gastric emptying time by 45% compared to baseline, measured via paracetamol absorption testing.

AM833 activates both GLP-1 and GIP receptors simultaneously. GLP-1 receptor agonism enhances glucose-dependent insulin secretion (reducing hypoglycemia risk), slows gastric emptying, and reduces appetite via hypothalamic signaling. GIP receptor agonism. The distinguishing factor from standard GLP-1 monotherapy. Amplifies insulin secretion in response to nutrient intake, enhances lipid metabolism, and may reduce inflammation in adipose tissue. Dual agonism creates additive metabolic effects: Phase 1 pharmacokinetic data from AM833 showed peak plasma concentration within 1–2 hours and a half-life of approximately 48 hours, shorter than cagrilintide but sufficient for daily dosing. The receptor selectivity profile. Roughly 1:1 binding affinity for GLP-1 and GIP receptors. Distinguishes it from tirzepatide, which has higher GIP receptor bias.

The practical research implication: cagrilintide's mechanism is gastric-dominant, making it valuable for studies focused on nutrient absorption timing, gastric motility disorders, or appetite regulation independent of incretin pathways. AM833's dual incretin action makes it relevant for glucose homeostasis studies, beta-cell function research, and metabolic syndrome models where both insulin sensitivity and appetite regulation matter. At Real Peptides, our synthesis process ensures exact amino-acid sequencing for both amylin analogs and incretin mimetics. The structural precision required for receptor binding studies.

Pharmacokinetics and Dosing Schedules

Cagrilintide's extended half-life of approximately 165 hours (7 days) allows weekly subcutaneous injection, matching the dosing schedule of semaglutide and liraglutide's once-weekly formulations. This extended duration comes from two structural modifications: an albumin-binding fatty acid side chain (similar to semaglutide's design) and amino acid substitutions that resist enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP). Steady-state plasma concentration is reached after 4–5 weeks of weekly dosing. The REWIND-1 trial used a 20-week dose escalation from 0.3mg to 4.5mg weekly, with most adverse events (nausea, vomiting) concentrated in the first 8 weeks during titration.

AM833 has a significantly shorter half-life. Approximately 40–50 hours based on early-phase pharmacokinetic modeling. Requiring daily subcutaneous administration to maintain therapeutic plasma levels. The shorter half-life reduces accumulation risk but necessitates more frequent dosing, which affects compliance in long-term metabolic studies. Peak plasma concentration (Tmax) occurs 1–2 hours post-injection, meaning glucose-lowering effects appear within the first 3 hours. Faster onset than weekly GLP-1 agonists but requiring coordination with meal timing in research protocols. The volume of distribution is moderate (approximately 10–15 liters), indicating limited tissue penetration beyond the vascular compartment.

Dosing schedule directly impacts study design. Weekly cagrilintide allows simpler protocols with fewer injection time points, reducing handling errors in multi-week studies. Daily AM833 requires precise timing windows and increases the likelihood of missed doses in behavioral models. For researchers evaluating FAT Loss Stack protocols that combine multiple peptides, half-life compatibility matters. Weekly peptides align cleanly, while daily peptides require separate tracking.

Clinical Trial Progress and Published Endpoints

Cagrilintide has completed Phase 2 trials and entered Phase 3 development as part of Novo Nordisk's CagriSema combination therapy (cagrilintide + semaglutide). The REWIND-1 Phase 2 trial (NCT03669432) enrolled 706 participants with obesity or overweight plus comorbidities, testing cagrilintide monotherapy at doses ranging from 0.3mg to 4.5mg weekly over 32 weeks. Results published in The Lancet showed dose-dependent weight reduction: 10.8% at the 2.4mg dose versus 3.1% placebo. Adverse events were predominantly gastrointestinal. Nausea (38%), vomiting (21%), diarrhea (16%). And most resolved within 8 weeks. The Phase 3 REDEFINE program launched in 2025, evaluating CagriSema at target doses of 2.4mg cagrilintide + 2.4mg semaglutide weekly, with primary endpoints including weight reduction and glycemic control in type 2 diabetes populations.

AM833 remains in Phase 1 and early Phase 2 development. Published pharmacokinetic data comes from single-ascending-dose (SAD) and multiple-ascending-dose (MAD) Phase 1 trials conducted between 2023–2025. These studies established maximum tolerated dose, characterized absorption and elimination kinetics, and identified the dose range for Phase 2 efficacy testing. No peer-reviewed efficacy data (weight loss, A1C reduction) has been published as of early 2026. The compound is approximately 3–4 years behind cagrilintide in the development timeline. Phase 2 trials expected to report in 2027 will provide the first direct efficacy comparison against existing GLP-1 monotherapies.

The trial stage gap means cagrilintide has significantly more published mechanistic and safety data available for research planning. AM833's profile remains largely predictive, based on structural similarity to tirzepatide and preclinical receptor binding assays. Researchers requiring established dosing protocols and adverse event profiles should prioritize cagrilintide; those investigating novel dual incretin mechanisms may find value in AM833 despite limited clinical data.

Cagrilintide vs AM833: Research Application Comparison

Key Takeaways

• Cagrilintide is a long-acting amylin receptor agonist with a 165-hour half-life, allowing once-weekly dosing and slowing gastric emptying by 45% in clinical trials.
• AM833 is a dual GLP-1 and GIP receptor agonist with a 40–50 hour half-life, requiring daily administration and targeting incretin pathways for glucose and appetite regulation.
• Cagrilintide has completed Phase 2 trials showing 10.8% weight reduction at 32 weeks and entered Phase 3 development in combination with semaglutide.
• AM833 remains in Phase 1/2 development with no published human efficacy data as of early 2026, making it 3–4 years behind cagrilintide in the clinical pipeline.
• The receptor mechanisms are fundamentally different. Cagrilintide activates amylin pathways independent of GLP-1, while AM833 mimics dual incretin signaling.
• For metabolic research requiring established dosing protocols and published endpoints, cagrilintide is the more validated compound; AM833 offers novelty but limited clinical data.

What If: Cagrilintide and AM833 Scenarios

What if I'm designing a study on gastric emptying and nutrient absorption — which peptide is appropriate?

Use cagrilintide. Its amylin receptor mechanism directly targets gastric motility, with Phase 2 data showing 45% reduction in gastric emptying time measured via paracetamol absorption. AM833's GLP-1 component does slow gastric emptying, but the effect is secondary to incretin signaling and less pronounced than amylin-specific agonism. If your research question centers on how delayed nutrient delivery affects absorption kinetics, cagrilintide provides the stronger, more selective intervention.

What if I need a peptide for glucose homeostasis research in a diabetic model — does the mechanism difference matter?

Yes. AM833's dual GLP-1/GIP agonism directly enhances glucose-dependent insulin secretion, making it mechanistically aligned with diabetes research. Cagrilintide suppresses glucagon (reducing hepatic glucose output) but doesn't directly stimulate insulin release. Its glucose-lowering effect is indirect via delayed carbohydrate absorption. For studies evaluating beta-cell function or insulin sensitivity, AM833's incretin mechanism is the appropriate choice despite its earlier development stage.

What if I'm combining peptides in a metabolic protocol — are cagrilintide and AM833 compatible?

They target distinct receptor pathways, so mechanistic overlap is minimal. But practical compatibility depends on dosing schedules and side effect profiles. Cagrilintide's weekly schedule aligns cleanly with other weekly peptides; AM833's daily dosing complicates multi-peptide protocols. Both cause GI side effects during titration, and combining them could compound nausea and vomiting, potentially limiting tolerable doses. The FAT Loss Metabolic Health Bundle demonstrates how peptide stacking requires careful attention to pharmacokinetic alignment and cumulative adverse event risk.

The Mechanistic Truth About Cagrilintide vs AM833

Here's the honest answer: these peptides aren't alternatives to each other. They're tools for fundamentally different research questions. Cagrilintide is a gastric brake. AM833 is an incretin amplifier. If your hypothesis depends on how slowing nutrient delivery affects metabolic outcomes, cagrilintide is the correct compound. If your model requires direct insulin secretion enhancement or dual receptor activation, AM833 is appropriate. The confusion arises because both reduce body weight in preclinical models. But the pathways to that outcome are mechanistically distinct, and choosing the wrong one based on a shared endpoint will produce results that don't answer your research question. Cagrilintide's Phase 3 status also means it has published safety data, established dosing protocols, and peer-reviewed efficacy endpoints. AM833 has early-phase pharmacokinetics and a promising receptor profile. But no human efficacy data yet. Researchers selecting AM833 should plan for protocol adjustments as Phase 2 data emerges.

Structural Design and Receptor Binding Profiles

Cagrilintide is a 37-amino-acid analog of human amylin (also called islet amyloid polypeptide, or IAPP), modified with a C16 fatty acid side chain and amino acid substitutions at positions 25 and 28 to enhance stability and albumin binding. The native amylin structure is prone to aggregation and fibrillation. One reason endogenous amylin dysregulation contributes to beta-cell dysfunction in type 2 diabetes. Cagrilintide's modifications prevent aggregation while preserving binding affinity to the amylin receptor, a heterodimeric complex formed by the calcitonin receptor (CTR) and one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). Binding to CTR/RAMP complexes in the area postrema and brainstem activates satiety signaling, while binding in the stomach wall directly inhibits gastric smooth muscle contraction.

AM833 is a synthetic peptide designed with structural features optimized for dual GLP-1 and GIP receptor binding. Exact sequence data remains proprietary, but Phase 1 receptor binding assays indicate roughly 1:1 affinity for GLP-1 and GIP receptors. Contrasting with tirzepatide, which shows 5:1 GIP:GLP-1 bias. The balanced affinity means AM833 should produce insulin secretion effects comparable to GLP-1 monotherapy while adding GIP-mediated lipid metabolism and adipose tissue remodeling. Structural resistance to DPP-4 degradation extends the half-life beyond native GLP-1 (which degrades within 2–3 minutes), though not to the 7-day duration of cagrilintide.

These structural differences dictate experimental use cases. Cagrilintide's amylin specificity makes it irreplaceable for studies isolating amylin receptor function from incretin pathways. AM833's balanced dual agonism allows direct comparison with GLP-1 monotherapy (e.g., semaglutide, liraglutide) and GIP-biased dual agonists (tirzepatide) in the same study design. For researchers evaluating receptor-specific metabolic contributions, having access to compounds spanning the amylin-GLP-1-GIP spectrum matters. Which is why our full peptide collection includes both amylin analogs and incretin mimetics with exact amino-acid sequencing verified at every synthesis batch.

What researchers selecting between cagrilintide and AM833 need to understand is that 'what's the difference' isn't just a pharmacokinetic question. It's a question about which biological system your research interrogates. Amylin controls the gut. GLP-1 and GIP control the pancreas and fat. Both reduce weight, but through pathways that don't overlap. If your study conflates them, your results won't clarify mechanism. They'll muddy it. Choose the peptide that matches the receptor system your hypothesis requires, not the one with the most impressive weight loss percentage in a press release.